Drugs / SYH2051
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06011291 | Aug 2023 → Dec 2024 | head and neck cancer | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06775236 | Mar 2025 → Jun 2027 expected | breast cancer | CSPC Megalith Biopharmaceutical Co.,Ltd. | Not yet recruiting | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT07104877 | Apr → Nov 2024 overdue | colorectal cancer, gastric cancer | Fujian Cancer Hospital | Active not recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SYH2051 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06011291 ↗ |
| Action | Inhibit | “Selective ATM protein kinase inhibitor” NCT06775236 ↗ |
| Route | Oral | “oral” NCT06775236 ↗ |
| Target | ATM | “Selective ATM protein kinase inhibitor” NCT06775236 ↗ |